Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 3Phase 1/2 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Burkitt Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1

Interventions

pembrolizumab 133Carboplatin 132Cisplatin 119Paclitaxel 104Gemcitabine 89Specimen Handling 82Magnetic Resonance Spectroscopy 82Docetaxel 73Dexamethasone 60Cyclophosphamide 60Pemetrexed 57durvalumab 55Bevacizumab 55Capecitabine 54Radiotherapy 51Doxorubicin 51Oxaliplatin 50Fluorouracil 48Radiation 47Rituximab 43Leucovorin 43Vincristine 41Lenalidomide 40Etoposide 39atezolizumab 37Nivolumab 37Letrozole 36130-nm albumin-bound paclitaxel 32Bortezomib 31Prednisone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Inotuzumab Ozogamicin × 90 days × Clear all
NCT03150693 2026-06-02

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Alliance for Clinical Trials in Oncology

Phase 3 Recruiting
310 enrolled
Lymphoid

Burkitt Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

NCT07476729 2026-03-17

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

Charite University, Berlin, Germany

Phase 3 Not yet recruiting
750 enrolled
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡